Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects

PHASE3CompletedINTERVENTIONAL

Enrollment

558

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions

Active, Symptomatic Blepharitis

Interventions

DRUG

ISV-305

Dexamethasone in DuraSite® 2 twice daily for 2 weeks

OTHER

Vehicle

Vehicle twice daily for 2 weeks

Trial Locations (1)

Clinical Research Center, Newport Beach

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT01543490 - Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects | Biotech Hunter | Biotech Hunter